ArticleMalariaWorld journal2026
No G6PD A- (G202A) variant detected among
Article in MalariaWorld journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, prevalent in malaria-endemic regions, has been associated with a reduced risk of severe malaria due to impaired parasite growth in deficient erythrocytes. The G6PD gene, located on the X chromosome, harbours various mutations associated with differing enzyme activity levels. This study investigates the prevalence of G6PD deficiency variants and their impact on parasite density and haemoglobin levels among malaria-positive patients in Awka, Anambra State, Nigeria. Materials and Methods: Blood samples were collected from 100 malaria positive participants; 64 participants with complete genotyping and clinical data were included in the analysis and screened for the A376G and G202A variants using PCR and Sanger sequencing. Results: Molecular analysis indicated that the B variant (normal) was predominant, with 83% of the participants possessing this variant. None of the participants tested had the A- variant, associated with G6PD defciency, suggesting no evidence of the G202A (A-) variant in this hospital-based sample. The B variant and the A+ variant showed no significant impact on the haemoglobin and parasitaemia levels of the study participants. Conclusions: The findings support the absence of the G202A (A-) variant in this cohort and show no detectable differences in parasitaemia or haemoglobin between A+ and B genotypes. Broader genotyping and/or G6PD enzyme activity testing in community representative samples is recommended before drawing population-level conclusions or informing treatment policy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.